Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis

Ang2, the instigator of inflammation

(2011) H. Kim et al.   BLOOD

Angiopoietin-2 promotes myeloid cell infiltration in a  2-integrin-dependent manner

(2011) A. Scholz et al.   BLOOD

Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth

(2011) H. Huang et al.   CLINICAL CANCER RESEARCH

AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer

(2011) Ewan JD Robson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Double Anti-angiogenic and Anti-inflammatory Protein Valpha Targeting VEGF-A and TNF-α in Retinopathy and Psoriasis

(2011) Keehoon Jung et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Emerging antibody combinations in oncology

(2011) Stephen J. Demarest et al.   mAbs

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity

(2011) Jianying Dong et al.   mAbs

Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth

(2010) H. Hashizume et al.   CANCER RESEARCH

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

(2010) A. C. Mita et al.   CLINICAL CANCER RESEARCH

Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1β, TNF-α, and LPS

(2010) Veronika Makó et al.   CYTOMETRY PART A

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

(2010) J. L. Brown et al.   MOLECULAR CANCER THERAPEUTICS

Chemical generation of bispecific antibodies

(2010) V. R. Doppalapudi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Stability engineering of scFvs for the development of bispecific and multivalent antibodies

(2010) Brian R. Miller et al.   PROTEIN ENGINEERING DESIGN & SELECTION

TNF-  antagonists beyond approved indications: stories of success and prospects for the future

(2010) M. P. Karampetsou et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Serum angiopoietin-2 levels are elevated during acute exacerbations of COPD

(2010) Yu Ji CHO et al.   RESPIROLOGY

Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease

(2010) J. Westra et al.   RHEUMATOLOGY

Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease

(2010) Małgorzata Michalska-Jakubus et al.   RHEUMATOLOGY

Transmembrane TNF- : structure, function and interaction with anti-TNF agents

(2010) T. Horiuchi et al.   RHEUMATOLOGY

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

(2009) Zehra Kaymakcalan et al.   CLINICAL IMMUNOLOGY

VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration

(2009) James A Dixon et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Angiopoietin-2 in experimental colitis

(2009) Vijay C. Ganta et al.   INFLAMMATORY BOWEL DISEASES

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

(2009) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Adverse effects of anticancer agents that target the VEGF pathway

(2009) Helen X. Chen et al.   Nature Reviews Clinical Oncology

Treatment of rheumatoid arthritis: state of the art 2009

(2009) Ronald F. van Vollenhoven   Nature Reviews Rheumatology

The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus

(2008) P Kumpers et al.   ANNALS OF THE RHEUMATIC DISEASES

Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab

(2008) Hiroki Mitoma et al.   ARTHRITIS AND RHEUMATISM

Characterization of a novel anti-human TNF-α murine monoclonal antibody with high binding affinity and neutralizing activity

(2008) Moo-Young Song et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Neutralizing Anti-Vascular Endothelial Growth Factor (VEGF) Antibody Reduces Severity of Experimental Ulcerative Colitis in Rats: Direct Evidence for the Pathogenic Role of VEGF

(2008) G. Tolstanova et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS